Fresenius SE & Co. (OTCMKTS:FSNUY) Sees Significant Decline in Short Interest

Fresenius SE & Co. (OTCMKTS:FSNUY) was the target of a significant drop in short interest in the month of May. As of May 15th, there was short interest totaling 49,381 shares, a drop of 65.8% from the April 30th total of 144,231 shares. Based on an average trading volume of 338,840 shares, the short-interest ratio is currently 0.1 days. Approximately 0.0% of the shares of the company are sold short.

Analyst Ratings Changes

Several research analysts have weighed in on the stock. Citigroup reiterated a “buy” rating on shares of Fresenius SE & Co. in a research report on Tuesday, February 3rd. Morgan Stanley restated an “overweight” rating on shares of Fresenius SE & Co. in a research report on Monday, April 20th. Three equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy”.

Fresenius SE & Co. Price Performance

FSNUY traded down $0.28 during trading on Monday, hitting $10.36. 165,539 shares of the company traded hands, compared to its average volume of 110,087. The company has a market cap of $23.34 billion, a PE ratio of 13.81 and a beta of 0.64. The stock’s 50-day simple moving average is $12.23 and its two-hundred day simple moving average is $13.56. Fresenius SE & Co. has a 1 year low of $10.34 and a 1 year high of $33.93. The company has a current ratio of 1.32, a quick ratio of 1.00 and a debt-to-equity ratio of 0.47.

Fresenius SE & Co. (OTCMKTS:FSNUY) last posted its earnings results on Wednesday, May 6th. The company reported $0.24 earnings per share for the quarter, missing the consensus estimate of $0.25 by ($0.01). The company had revenue of $6.75 billion for the quarter, compared to analysts’ expectations of $6.79 billion. Fresenius SE & Co. had a net margin of 6.55% and a return on equity of 10.29%. As a group, sell-side analysts anticipate that Fresenius SE & Co. will post 1.05 earnings per share for the current fiscal year.

Fresenius SE & Co. Company Profile

Fresenius SE & Co KGaA is a global healthcare group headquartered in Bad Homburg vor der Höhe, Germany. Founded in 1912 by Eduard Fresenius, the company has grown into one of the world’s leading providers of products and services for dialysis, hospitals and outpatient medical care. Trading on major European exchanges and available over the counter in the U.S. as FSNUY, Fresenius SE & Co brings together a portfolio of specialized healthcare businesses under one corporate umbrella.

The company operates through four main business segments.